CURRENT USE AND OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION: BRAZILIAN SUMMARY SLIDES – 2024
Authors: Simione Anderson João , Silva Cinthya Corrêa da , Sabaini Paula Moreira da Silva , Macedo Antonio Vaz , Neves Heliz Regina Alves das , Geraldo Bruna Letícia da Silva Santos , Ammi Monique , Costa Flavia Ferreira da , Viana Valeria , Cavilha Adriana Mendes de Quadros , Concilio Rosana Rocha , Colturato Vergilio Antonio Rensi , Scheinberg Phillip , Nabhan Samir Kanaan , Lerner Decio , Hamerschlak Nelson , Colella Marcos Paulo , Barros George Maurício Navarro , Silvério Alexandre , Seber Adriana , Novis Yana Augusta Sarkis , Rocha Vanderson Geraldo , Moreira Maria Claudia Rodrigues , Astigarraga Claudia Caceres , Daudt Liane Esteves , Macedo Maria Cristina Martins de Almeida , Chiattone Ricardo , Fernandes Juliana Folloni , Vilela Volney Assis Lara , Soares Rodolfo Daniel de Almeida , Teixeira Gustavo Machado , Rodrigues Celso Arrais- , Silva Roberto Luiz da , Funke Vaneuza Araújo Moreira , Vigorito Afonso Celso , Arcuri Leonardo Javier , Filho Jayr Schmidt , Molla Vinicius Campos de , Farias João Samuel de Holanda , Pasquini Ricardo , Bonfim Carmem Maria Sales , Neto Abrahão Elias Hallack , Calixto Rodolfo Froes , Bouzas Luis Fernando , Feliciano João Victor Piccolo , Gaiolla Rafael Dezen , Capra Marcelo , Atalla Angelo , Aranha Milton Alexandre Ferreira , Schaffel Rony , Veloso Gianne Donato Costa , Bettarello Gustavo , Melo Andresa Lima , Franco Simone de Castro Resende , Pasquini Marcelo C. , Duarte Fernando Barroso 
Published: May 2024

The development of the Brazilian Registry of Hematopoietic Cell Transplantation in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR) allowed for an assessment of the activity and general outcomes of transplants in Brazil. Here, we report an updated activity. Brazilian transplant centers report their data to the CIBMTR, using the FormsNet3 platform. Information returns to Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) through the Data Back to Centers (DBtC) tool. Data from patients who received an HCT from 2012 to 2023 from Brazilian centers were extracted from CIBMTR. Descriptive analysis was carried out by patient-, disease- and transplant-specific variables and overall survival analysis using Kaplan Meyer. A total of 12,230 patients were eligible for this study (5,573 autologous and 6,657 allogeneic transplants). The number of reporting centers increased from 40 to 44 during the period. The most common HCT indication in Brazil is AML for allogeneic HCT with 152 transplants year and multiple myeloma for autologous HCT with 245 transplants per year. Among allogeneic HCT, in the last 4 years, mismatched related donor was the main source of donors. Regarding the graft source for allogeneic transplants, BM was the most frequent among pediatric transplants, while PBSC was the most used in adults. Infections were the leading cause of death in the first 100 days after all types of transplants. Patients with acute leukemia who underwent HCT with advanced stage disease had lower survival rates compared to those at other stages. Despite the differences in the number of cases and follow-up time, the results in this study were similar to those presented in the United States (US) Summary Slides.